Literature DB >> 19538000

Opioid dependence treatment: options in pharmacotherapy.

Angela L Stotts1, Carrie L Dodrill, Thomas R Kosten.   

Abstract

The development of effective treatments for opioid dependence is of great importance given the devastating consequences of the disease. Pharmacotherapies for opioid addiction include opioid agonists, partial agonists, opioid antagonists, and alpha-2-adrenergic agonists, which are targeted toward either detoxification or long-term agonist maintenance. Agonist maintenance therapy is currently the recommended treatment for opioid dependence due to its superior outcomes relative to detoxification. Detoxification protocols have limited long-term efficacy, and patient discomfort remains a significant therapy challenge. Buprenorphine's effectiveness relative to methadone remains a controversy and may be most appropriate for patients in need of low doses of agonist treatment. Buprenorphine appears superior to alpha-2 agonists, however, and office-based treatment with buprenorphine in the USA is gaining support. Studies of sustained-release formulations of naltrexone suggest improved effectiveness for retention and sustained abstinence; however, randomized clinical trials are needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538000      PMCID: PMC2874458          DOI: 10.1517/14656560903037168

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  136 in total

1.  Recent evolution in opiate dependence in France during generalisation of maintenance treatments.

Authors:  X Thirion; J Micallef; K Barrau; S Djezzar; H Lambert; J L Sanmarco; G Lagier
Journal:  Drug Alcohol Depend       Date:  2001-02-01       Impact factor: 4.492

2.  Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers.

Authors:  E Vining; T R Kosten; H D Kleber
Journal:  Br J Addict       Date:  1988-05

Review 3.  Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection.

Authors:  Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali
Journal:  J Gen Intern Med       Date:  2005-12-07       Impact factor: 5.128

4.  Naltrexone shortened opioid detoxification with buprenorphine.

Authors:  A Umbricht; I D Montoya; D R Hoover; K L Demuth; C T Chiang; K L Preston
Journal:  Drug Alcohol Depend       Date:  1999-10-01       Impact factor: 4.492

Review 5.  Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM).

Authors:  R L Deamer; D R Wilson; D S Clark; J G Prichard
Journal:  J Addict Dis       Date:  2001

6.  Sustained-release naltrexone for alcoholism treatment: a preliminary study.

Authors:  H R Kranzler; V Modesto-Lowe; E S Nuwayser
Journal:  Alcohol Clin Exp Res       Date:  1998-08       Impact factor: 3.455

7.  Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Authors:  S L Walsh; K L Preston; G E Bigelow; M L Stitzer
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

8.  Unplanned admissions to two Sydney public hospitals after naltrexone implants.

Authors:  Nicholas Lintzeris; Soung Lee; Lucinda Scopelliti; James Mabbutt; Paul S Haber
Journal:  Med J Aust       Date:  2008-04-21       Impact factor: 7.738

9.  Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study.

Authors:  Marina Davoli; Anna M Bargagli; Carlo A Perucci; Patrizia Schifano; Valeria Belleudi; Matthew Hickman; Giuseppe Salamina; Roberto Diecidue; Federica Vigna-Taglianti; Fabrizio Faggiano
Journal:  Addiction       Date:  2007-12       Impact factor: 6.526

10.  Withdrawal from methadone maintenance. Rate of withdrawal and expectation.

Authors:  E C Senay; W Dorus; F Goldberg; W Thornton
Journal:  Arch Gen Psychiatry       Date:  1977-03
View more
  88 in total

1.  Pharmacokinetics of a new immediate-release methadone tablet formulation with decreased in vitro solubility.

Authors:  Robert K Vinson
Journal:  Clin Drug Investig       Date:  2012-07-01       Impact factor: 2.859

Review 2.  Retention in medication-assisted treatment for opiate dependence: A systematic review.

Authors:  Christine Timko; Nicole R Schultz; Michael A Cucciare; Lisa Vittorio; Christina Garrison-Diehn
Journal:  J Addict Dis       Date:  2015-10-14

3.  Opioid-related US hospital discharges by type, 1993-2016.

Authors:  Cora Peterson; Likang Xu; Curtis Florence; Karin A Mack
Journal:  J Subst Abuse Treat       Date:  2019-05-10

4.  Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Authors:  Yunyun Yuan; Saheem A Zaidi; Orgil Elbegdorj; Lindsey C K Aschenbach; Guo Li; David L Stevens; Krista L Scoggins; William L Dewey; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2013-11-07       Impact factor: 7.446

5.  Interim treatment: Bridging delays to opioid treatment access.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2015-04-30       Impact factor: 4.018

6.  Comorbid substance use diagnoses and partner violence among offenders receiving pharmacotherapy for opioid dependence.

Authors:  Cory A Crane; Robert C Schlauch; Susan Devine; Caroline J Easton
Journal:  J Addict Dis       Date:  2016-02-22

7.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; Abdulmajeed M Jali; Bharath Peddibhotla; Dwight A Williams; Chuanchun Zou; David L Stevens; William L Dewey; Hamid I Akbarali; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2019-01-11       Impact factor: 7.446

8.  "This is not who I want to be:" experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment.

Authors:  Sarah K Moore; Honoria Guarino; Lisa A Marsch
Journal:  Subst Use Misuse       Date:  2013-09-16       Impact factor: 2.164

9.  Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.

Authors:  J J Taylor; M Laudenbach; A M Tucker; M K Jenkins; M Pravetoni
Journal:  J Immunol Methods       Date:  2014-01-23       Impact factor: 2.303

10.  Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure.

Authors:  Alison Oliveto; Michael Mancino; Nichole Sanders; Christopher Cargile; J Benjamin Guise; Warren Bickel; W Brooks Gentry
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.